Table 3. 2025 targets for key populations.
Intervention | SWs | MSM | TG | Prisoners and others in closed settings | PWID | Applies to |
---|---|---|---|---|---|---|
Condoms/lube | 90% | 95% | 95% | 90% | 95% | Use at last sex by people not taking PrEP and who have nonregular partner whose HIV viral load status is not known to be undetectable |
PrEP | Uninfected population | |||||
Very high risk | 80% | 50% | 50% | 15% | 15% | |
High risk | 15% | 15% | 15% | 5% | 5% | |
Low risk | 0% | 0% | 0% | 0% | 0% | |
Sterile needles and syringes | 90% | 90% | PWID | |||
OST | 50% | People who are opioid dependent | ||||
STI screening and treatment | 80% | 80% | 80% | People with symptoms of STIs | ||
Appropriate health or community-led services | 90% | 90% | 90% | 100% | 90% | All |
PEP (nonoccupational exposure) | 90% | 90% | 90% | 90% | 90% | Those with recent exposure |
Knowledge of status | 95% | 95% | 95% | 95% | 95% | PLHIV |
On ART | 95% | 95% | 95% | 95% | 95% | PLHIV who know their status |
Virally suppressed | 95% | 95% | 95% | 95% | 95% | PLHIV on ART |
ART, antiretroviral therapy; MSM, men who have sex with men; OST, opioid substitution therapy; PEP, postexposure prophylaxis; PLHIV, people living with HIV; PrEP, pre-exposure prophylaxis; PWID, people who inject drugs; STI, sexually transmitted infection; SW, sex worker; TG, transgender people.